摘要
AIM: To investigate the value of interleukin-8 (IL-8), a pro-inflammatory chemokine, in predicting the prognosis of pancreatic cancer. METHODS: Expression of IL-8 and its receptor CXCR1 was assessed by immunohistochemistry in pancreatic cancer and chronic pancreatitis samples. Enzyme-linked immunosorbent assay was used to detect the serum IL-8 levels in pancreatic cancer patients. Human pancreatic cancer tissues were heterotopically transplanted to the immune-deficiency mice to evaluate the effect of serum IL-8 on the tumorigenesis of the cancer samples.RESULTS: IL-8 and CXCR1 proteins were both overexpressed in pancreatic adenocarcinoma samples (55.6% and 65.4%, respectively) compared with the matched para-cancer tissues (25.9% and 12.3%, P < 0.01), or chronic pancreatitis (0% and 25%, P < 0.05). Serum IL-8 levels in pancreatic cancer patients (271.1 ± 187.7 ng/mL) were higher than in other digestive system tumors, such as gastric cancer (41.77 ± 9.11 ng/mL, P = 0.025), colorectal carcinoma (78.72 ± 80.60 ng/mL, P = 0.032) and hepatocellular carcinoma (59.60 ± 19.80 ng/mL, P = 0.016). In vivo tumorigenesis analysis further proved that tumor tissues from patients with higher serum IL-8 levels grew faster than those with lower IL-8 levels. CONCLUSION: IL-8 can be a fine serum marker for predicting the prognosis pancreatic cancer.
AIM： To investigate the value of interleukin-8 （IL-8）, a pro-inflammatory chemokine, in predicting the prognosis of pancreatic cancer. METHODS： Expression of IL-8 and its receptor CXCR1 was assessed by immunohistochemistry in pancreatic cancer and chronic pancreatitis samples. Enzyme-linked immunosorbent assay was used to detect the serum IL-8 levels in pancreatic cancer patients. Human pancreatic cancer tissues were heterotopically transplanted to the immune-deficiency mice to evaluate the effect of serum IL-8 on the tumorigenesis of the cancer samples.RESULTS： IL-8 and CXCR1 proteins were both overexpressed in pancreatic adenocarcinoma samples （55.6% and 65.4%, respectively） compared with the matched para-cancer tissues （25.9% and 12.3%, P 〈 0.01）, or chronic pancreatitis （0% and 25%, P 〈 0.05）. Serum IL-8 levels in pancreatic cancer patients （271.1 ± 187.7 ng/mL） were higher than in other digestive system tumors, such as gastric cancer （41.77 ± 9.11 ng/mL, P = 0.025）, colorectal carcinoma （78.72 ± 80.60 ng/mL, P = 0.032） and hepatocellular carcinoma （59.60 ± 19.80 ng/mL, P = 0.016）. In vivo tumorigenesis analysis further proved that tumor tissues from patients with higher serum IL-8 levels grew faster than those with lower IL-8 levels. CONCLUSION： IL-8 can be a fine serum marker for predicting the prognosis pancreatic cancer.
基金
Supported by The National Key Project of Scientific and Technical Supporting Programs of China, No. 2006BAI02A14
National Natural Science Foundation of China, No. 30770996 and No. 30901776
